par Schreiber, Jonas ;McNally, John;Chodavarapu, Krishna;Svarovskaia, Evguenia;Moreno, Christophe
Référence Hepatology, 64, 3, page (983-985)
Publication Publié, 2016
Référence Hepatology, 64, 3, page (983-985)
Publication Publié, 2016
Article révisé par les pairs
Résumé : | During a phase 3 study evaluating the combination of sofosbuvir-velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV. This patient tolerated the study regimen well and achieved sustained virological response 12 weeks after treatment (SVR12). (Hepatology 2016;64:983-985). |